Functional characterization of nonmetastatic paraganglioma and pheochromocytoma by (18) F-FDOPA PET: focus on missed lesions

Autor: Arnaud Deveze, David Taïeb, Isabelle Morange, Clara C. Chen, Elise M. Blanchet, Sophie Gabriel, Frederic Sebag, Anne Barlier, Nicolas Fakhry, Karel Pacak
Přispěvatelé: Service de chirurgie générale et endocrinienne, Hôpital de la Timone [CHU - APHM] (TIMONE), Laboratoire de Biomécanique Appliquée (LBA UMR T24), Aix Marseille Université (AMU)-Université Gustave Eiffel, Centre de recherche en neurobiologie - neurophysiologie de Marseille (CRN2M), Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)
Jazyk: angličtina
Rok vydání: 2013
Předmět:
medicine.medical_specialty
MESH: Paraganglioma
Endocrinology
Diabetes and Metabolism

Adrenal Gland Neoplasm
Adrenal Gland Neoplasms
Pheochromocytoma
MESH: Dihydroxyphenylalanine
Article
030218 nuclear medicine & medical imaging
Paraganglioma
Lesion
03 medical and health sciences
0302 clinical medicine
Endocrinology
Germline mutation
Internal medicine
Humans
Medicine
Abdominal Neoplasms
MESH: Pheochromocytoma
[SDV.BBM.BC]Life Sciences [q-bio]/Biochemistry
Molecular Biology/Biochemistry [q-bio.BM]

False Negative Reactions
Retrospective Studies
MESH: False Negative Reactions
MESH: Humans
medicine.diagnostic_test
business.industry
Retrospective cohort study
MESH: Retrospective Studies
MESH: Abdominal Neoplasms
medicine.disease
MESH: Adrenal Gland Neoplasms
MESH: Succinate Dehydrogenase
MESH: Positron-Emission Tomography
Dihydroxyphenylalanine
3. Good health
Succinate Dehydrogenase
MESH: Head and Neck Neoplasms
Head and Neck Neoplasms
Positron emission tomography
Positron-Emission Tomography
030220 oncology & carcinogenesis
medicine.symptom
business
Zdroj: Clinical Endocrinology
Clinical Endocrinology, Wiley, 2013, 79 (2), pp.170-7. ⟨10.1111/cen.12126⟩
Clinical Endocrinology, 2013, 79 (2), pp.170-7. ⟨10.1111/cen.12126⟩
ISSN: 0300-0664
1365-2265
DOI: 10.1111/cen.12126⟩
Popis: International audience; AIMS AND METHODS: To evaluate the clinical value of (18) F-fluorodihydroxyphenylalanine ((18) F-FDOPA) PET in relation to tumour localization and the patient's genetic status in a large series of pheochromocytoma/paraganglioma (PHEO/PGL) patients and to discuss in detail false-negative results. A retrospective study of PGL patients who were investigated with (18) F-FDOPA PET or PET/CT imaging in two academic endocrine tumour centres was conducted (La Timone University Hospital, Marseilles, France and National Institutes of Health (NIH), Bethesda, MD, USA). RESULTS: One hundred sixteen patients (39*7% harbouring germline mutations in known disease susceptibility genes) were evaluated for a total of 195 PHEO/PGL foci. (18) F-FDOPA PET correctly detected 179 lesions (91*8%) in 107 patients (92*2%). Lesion-based sensitivities for parasympathetic PGLs (head, neck, or anterior/middle thoracic ones), PHEOs, and extra-adrenal sympathetic (abdominal or posterior thoracic) PGLs were 98*2% [96*5% for Timone and 100% for NIH], 93*9% [93*8 and 93*9%] and 70*3% [47*1 and 90%] respectively (P < 0*001). Sympathetic (adrenal and extra-adrenal) SDHx-related PGLs were at a higher risk for negative (18) F-FDOPA PET than non-SDHx-related PGLs (14/24 vs 0/62, respectively, P < 0*001). In contrast, the risk of negative (18) F-FDOPA PET was lower for parasympathetic PGLs regardless of the genetic background (1/90 in SDHx vs 1/19 in non-SDHx tumours, P = 0*32). (18) F-FDOPA PET failed to detect two head and neck PGLs (HNPGL), likely due to their small size, whereas most missed sympathetic PGL were larger and may have exhibited a specific (18) F-FDOPA-negative imaging phenotype. (18) F-FDG PET detected all the missed sympathetic lesions. CONCLUSIONS: (18) F-FDOPA PET appears to be a very sensitive functional imaging tool for HNPGL regardless of the genetic status of the tumours. Patients with false-negative tumours on (18) F-FDOPA PET should be tested for SDHx mutations.
Databáze: OpenAIRE